- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05387083
A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05
A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Single-Center, Human Tick Kill Proof-of-Concept Study Evaluating the Safety, Tolerability, and Whole Blood Concentration of TP-05 (Lotilaner) in Healthy Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will consist of a screening period of no more than 30 days. Participants will come to the study center on Day -1 for tick placements on the skin. Nymphal ticks that have been tested negative for human pathogens and are known to be ready to attach will be placed.
On Day 1, the number of attached, live ticks will be counted. Participants will be randomized on Day 1 to receive either low dose or high dose of TP-05 or placebo. Tick attachment and mortality will be completed on Day 1 and after participants' return to the study center on Day 2 (24 hours after dosing). Participants will have ticks removed from the skin at the study center after the Day 2 (24 hours) tick count.
Participants will come to the study center on Day 30 for another placement of ticks on the skin. Tick attachment and mortality will be determined on Day 30 and on Day 31 (24 hours after placement).
Participants will complete the treatment period at Day 60. Participants will undergo a long-term safety follow-up period which will include additional safety and PK visits through Day 301.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jeremy Lim, PharmD
- Phone Number: 949-344-2657
- Email: JLim@tarsusrx.com
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Tufts University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participant must be 18 to 59 years of age inclusive, at the time of signing the informed consent.
- Participants who are overtly healthy as determined by medical evaluation including having no clinically significant diseases captured in the medical history or evidence of clinically significant findings on the physical examination.
- Participants who are non- or ex-smokers.
- Willingness to comply with all study procedures and availability for the duration of the study.
- BMI within the range 18 - 32 kg/m2
- Willingness to comply with contraceptive requirements
- Capable of giving signed informed consent
Exclusion Criteria:
- Female who is lactating at Screening.
- Female who is pregnant according to the serum pregnancy test at Screening or prior to study treatment administration.
- History of significant hypersensitivity to lotilaner or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs.
- Presence or history of significant gastrointestinal, metabolic, liver or kidney disease, or surgery that may affect drug bioavailability (excluding appendectomy).
- History of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic, or dermatologic disease.
- Have a history of malignancy (or active malignancy), with the exception of treated basal cell or squamous cell carcinoma.
- Presence of clinically significant ECG abnormalities at Screening, as defined by the Investigator.
- Maintenance therapy with any drug or significant history of drug dependency or alcohol abuse.
- Any clinically significant illness in the 28 days prior to study treatment administration.
- Known history of chronic infectious disease.
- History of allergy to surgical tape, hydrocolloid, or dressing.
- History of severe reactions to tick bites (granuloma or systemic reactions).
- Use of any non-prescription or prescription drugs (with the exception of hormonal contraceptives, hormone replacement therapy, acetaminophen) in the 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to study treatment administration.
- Use of St. John's wort in the 28 days prior to study treatment administration.
- Intake of lotilaner in the 6 months prior to study treatment administration.
- Treatment with an investigational drug within 30 days or 5 times the half-life (whichever is longer) prior to Screening.
- History of live attenuated vaccine within 4 weeks prior to randomization or requirement to receive these vaccinations at any time during the study.
- Any other clinically significant abnormalities in laboratory test results at Screening that would, in the opinion of the Investigator, increase the participant's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data.
- Blood donation of approximately 500 mL within 56 days prior to Screening.
- Plasma donation within 7 days prior to Screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low Dose of TP-05 (lotilaner)
Single Oral Low Dose of TP-05 tablet.
|
Healthy Volunteers will receive a single low dose of TP-05 on Day 1.
Other Names:
|
Experimental: High Dose of TP-05 (lotilaner)
Single Oral High Dose of TP-05 tablet.
|
Healthy Volunteers will receive a single high dose of TP-05 on Day 1.
Other Names:
|
Placebo Comparator: Placebo
Single Oral Dose of placebo tablet.
|
Healthy Volunteers will receive a single dose of placebo on Day 1.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Incidence of treatment emergent adverse events from baseline
Time Frame: Day -1 through Day 301
|
Safety and tolerability will be evaluated by incidence rate of treatment emergent adverse events from baseline.
|
Day -1 through Day 301
|
Clinically significant changes from Baseline chemistry laboratory tests
Time Frame: Day -1 through Day 301
|
Number of participants with clinically significant changes in clinical laboratory tests
|
Day -1 through Day 301
|
Clinically significant changes from Baseline hematology laboratory tests
Time Frame: Day -1 through Day 301
|
Number of participants with clinically significant changes in clinical laboratory tests
|
Day -1 through Day 301
|
Clinically significant changes from Baseline vital signs
Time Frame: Day -1 through Day 301
|
Number of participants with clinically significant changes in vital signs.
|
Day -1 through Day 301
|
Clinically significant changes from Baseline electrocardiograms (ECGs)
Time Frame: Day -1 through Day 301
|
Safety will be assessed by evaluating clinically significant changes from Baseline ECGs change in mean ventricular rate [beats/min]
|
Day -1 through Day 301
|
Clinically significant changes from Baseline electrocardiograms (ECGs) measures
Time Frame: Day -1 through Day 301
|
Safety will be assessed by evaluating clinically significant changes from Baseline ECGs change in pulse rate [msec]
|
Day -1 through Day 301
|
Clinically significant changes from Baseline QTC interval
Time Frame: Day -1 through Day 301
|
Safety will be assessed by evaluating clinically significant changes from Baseline ECGs change in QTC interval
|
Day -1 through Day 301
|
Clinically significant changes from Baseline QRS interval
Time Frame: Day -1 through Day 301
|
Safety will be assessed by evaluating clinically significant changes from Baseline ECGs change in QRS interval
|
Day -1 through Day 301
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
TP-05 on Tick Mortality
Time Frame: Day 2 through Day 31
|
Evaluate Tick Mortality after TP-05 administration.
|
Day 2 through Day 31
|
Evaluate the concentration of lotilaner in whole blood
Time Frame: Day -1 through Day 301
|
Measure of concentration of lotilaner in whole blood at specified timepoints
|
Day -1 through Day 301
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Jose Trevejo, CMO, Tarsus Pharmaceuticals, Inc.
- Principal Investigator: Linden Hu, MD, Tufts University School of Medicine
- Principal Investigator: Yoav Golan, Tufts Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- TRS-015
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteer
-
International Bio serviceNot yet recruitingHealthy Volunteer
-
International Bio serviceNot yet recruiting
-
Disc Medicine, IncRecruiting
-
National Cancer Institute (NCI)Recruiting
-
National Institute on Deafness and Other Communication...Recruiting
-
National Institute of Allergy and Infectious Diseases...RecruitingHealthy VolunteerUnited States
-
National Institute of Mental Health (NIMH)Recruiting
-
University Hospital, GrenobleCompletedHealthy VolunteerFrance
-
AbbVieActive, not recruitingHealthy VolunteerUnited States
-
Hospices Civils de LyonCompleted
Clinical Trials on Low Dose TP-05
-
Tarsus Pharmaceuticals, Inc.Completed
-
Tarsus Pharmaceuticals, Inc.Completed
-
Osel, Inc.University of California, San FranciscoCompletedBacterial VaginosisUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedPneumonia | Coronavirus Infection in 2019 (COVID-19) | Severe Acute Respiratory Syndrome (SARS) PneumoniaUnited States
-
MedImmune LLCCompletedNon-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)United States, Puerto Rico
-
Beijing Northland Biotech. Co., Ltd.CompletedSafety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.InfarctionAcute Myocardial InfarctionChina
-
Lucozade Ribena SuntoryKing's College LondonCompletedPostprandial PeriodUnited Kingdom
-
Indonesia UniversityMedika Natura Sdn BhdCompleted
-
Postgraduate Institute of Medical Education and...Completed